Veradermics, Incorporated
Financials
Valuation Metrics
Veradermics, Incorporated's Market Cap is $4.46B. Ranked #1434 of 3,121 in US market (top 46%), #937 of 1,658 on NYSE (top 57%), #85 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.46B | US#1,434/3,121 Sec#85/266 |
| Total Assets | $826M | US#2,561/3,121 Sec#118/266 |
| Net Assets | $814M | US#1,911/3,121 Sec#79/266 |
| Employees | 37 | US#2,741/3,121 Sec#217/266 |
| Value | ||
| P/B | 5.48x | US#2,302/3,121 Sec#150/266 |
| Financial Health | ||
| Debt Ratio | 1.49% | US#9/3,121 Sec#2/266 |
| Total Debt | $428000.00 | US#3,005/3,121 Sec#256/266 |
| Cash | $319M | US#1,370/3,121 Sec#79/266 |
| Current Ratio | 70.53x | US#45/3,121 Sec#3/266 |
| Performance | ||
| 1M Return | -4.13% | US#1,313/3,121 Sec#119/266 |
| From 52W High | -18.74% | US#1,308/3,121 Sec#91/266 |
| 1Y MDD | -24.84% | US#1,050/3,121 Sec#52/266 |
| Trading | ||
| Volume | 684,605 shares | US#1,801/3,121 Sec#190/266 |
| Trading Value | $73M | US#1,075/3,121 Sec#80/266 |
| Per Share | ||
| BPS | $19.47 | US#1,258/3,121 Sec#29/266 |
Company Info
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.